IMI – Myopia Control Reports Overview and Introduction

Authors

James S. Wolffsohn, Aston University, Birmingham, United Kingdom
Daniel Ian Flitcroft, Technological University DublinFollow
Kate L. Gifford, Queensland University of Technology, Queensland, Australia
Monica Jong, University of New South Wales, Sydney, New South Wales, Australia
Lyndon Jones, School of Optometry & Vision Science, University of Waterloo, Waterloo, Canada
Caroline C. W. Klaver, Radboud University Medical Center, Nijmegen, The Netherlands
Nicola S. Logan, Aston University, Birmingham, United Kingdom
Kovin Naidoo, University of KwaZulu-Natal, Durban, South Africa
Serge Resnikoff, University of New South Wales, Sydney, New South Wales, Australia
Padmaja Sankaridurg, University of New South Wales, Sydney, New South Wales, Australia
Earl L. Smith III, University of Houston, Houston, Texas, United States
David Troilo, State University of New York, New York, New York, United States
Christine F. Wildsoet, University of California Berkeley, Berkeley, California, United States

Document Type

Article

Rights

Available under a Creative Commons Attribution Non-Commercial Share Alike 4.0 International Licence

Disciplines

3.2 CLINICAL MEDICINE, Ophthalmology

Publication Details

Invest Ophthalmol Vis Sci. 2019;60:M1–M19. https://doi.org/ 10.1167/iovs.18-25980

Abstract

With the growing prevalence of myopia, already at epidemic levels in some countries, there is an urgent need for new management approaches. However, with the increasing number of research publications on the topic of myopia control, there is also a clear necessity for agreement and guidance on key issues, including on how myopia should be defined and how interventions, validated by well-conducted clinical trials, should be appropriately and ethically applied. The International Myopia Institute (IMI) reports the critical review and synthesis of the research evidence to date, from animal models, genetics, clinical studies, and randomized controlled trials, by more than 85 multidisciplinary experts in the field, as the basis for the recommendations contained therein. As background to the need for myopia control, the risk factors for myopia onset and progression are reviewed. The seven generated reports are summarized: (1) Defining and Classifying Myopia, (2) Experimental Models of Emmetropization and Myopia, (3) Myopia Genetics, (4) Interventions for Myopia Onset and Progression, (5) Clinical Myopia Control Trials and Instrumentation, (6) Industry Guidelines and Ethical Considerations for Myopia Control, and (7) Clinical Myopia Management Guidelines.

DOI

https://doi.org/ 10.1167/iovs.18-25980

Recommended Citation

Wolffsohn JS. et al.(2019) IMI – Myopia control reports overview and introduction. Invest Ophthalmol Vis Sci. 2019;60:M1–M19. doi: 10.1167/iovs.18-25980